ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Iron deficiency anemia is a common, treatable problem in children and young adults with Crohn’s disease. This trial is testing practical oral iron dosing strategies and collecting lab and microbiome data that could help guide safer, more effective iron treatment in this population.
Who Should Pay Attention
Pediatric and young-adult patients (ages 3–21) with Crohn’s disease and iron deficiency anemia, parents/caregivers, pediatric gastroenterologists, and researchers interested in iron therapy and the gut microbiome.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 4
Enrollment150 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This trial is recruiting at Weill Cornell Medicine and plans to enroll about 150 pediatric and young adult participants with biopsy-confirmed Crohn’s disease and iron deficiency anemia. It compares two specified oral-iron dosing strategies and a physician-directed arm, with laboratory outcomes tracked over time.
The protocol uses routine-care laboratory results and questionnaires and includes collection of gut bacteria information, suggesting exploratory microbiome-related analyses alongside iron biomarkers.
If you’re considering participation, the trial’s inclusion/exclusion criteria, dosing details by arm, and follow-up schedule (routine visits every 4–12 weeks, labs every ~6 months for some measures) are listed on the registry record; discuss specifics with the study team or your clinician.
Keep In Mind
This is a registered Phase 4 interventional trial on ClinicalTrials.gov that is currently recruiting at a single center (Weill Cornell Medicine). The record reports planned design, arms, and outcome measures but does not present results. Enrollment and conduct details should be confirmed with the study team.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorWeill Medical College of Cornell University
Trial IDNCT07925450
Study typeInterventional
Trial phasePhase 4
Enrollment150 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedNov 9, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
This trial is testing whether continued mirikizumab treatment helps children and teens with ulcerative colitis or Crohn’s disease achieve and maintain remission over the long term. Results could expand pediatric...
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Mirikizumab is being tested specifically in children with moderate-to-severe Crohn’s disease; successful results could expand treatment options for pediatric IBD. The study measures both symptom-based and endoscopic...
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
A Phase 3 study is testing whether upadacitinib is safe and effective for children with moderate-to-severe Crohn's disease who have not responded to or cannot take other therapies. Positive results could expand treatment...